{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:04:02Z","timestamp":1792728242411,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ijid.2021.09.064","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T05:53:29Z","timestamp":1632894809000},"page":"321-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015\u20132018"],"prefix":"10.1016","volume":"112","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-5216","authenticated-orcid":false,"given":"Dee","family":"Shortridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9297-263X","authenticated-orcid":false,"given":"Kelly A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5942-9707","authenticated-orcid":false,"given":"C. Andrew","family":"DeRyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl D.","family":"DePestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela A.","family":"Moise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2021.09.064_bib0001","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.chest.2020.06.034","article-title":"PROPHETIC: prospective identification of pneumonia in hospitalized patients in the ICU","volume":"158","author":"Bergin","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.ijid.2021.09.064_bib0002","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02461-20","article-title":"Molecular characterization of baseline Enterobacterales and Pseudomonas aeruginosa isolates from a Phase 3 nosocomial pneumonia (ASPECT-NP) clinical trial","volume":"65","author":"Castanheira","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.064_bib0003","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","year":"2018"},{"key":"10.1016\/j.ijid.2021.09.064_bib0004","series-title":"Performance standards for antimicrobial susceptibility testing: 30th informational supplement. M100Ed30","year":"2020"},{"key":"10.1016\/j.ijid.2021.09.064_bib0005","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.064_bib0006","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012)","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2021.09.064_bib0007","doi-asserted-by":"crossref","first-page":"e02340","DOI":"10.1128\/AAC.02340-18","article-title":"A case\u2013control study of real-life experience with ceftolozane-tazobactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection","volume":"63","author":"Fernandez-Cruz","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.064_bib0008","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijid.2021.09.064_bib0009","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ofid\/ofy346","article-title":"The importance of antimicrobial resistance monitoring worldwide and the origins of SENTRY Antimicrobial Surveillance Program","volume":"6","author":"Fuhrmeister","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2021.09.064_bib0010","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012\u20132017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2021.09.064_bib0011","doi-asserted-by":"crossref","first-page":"e02291","DOI":"10.1128\/AAC.02291-19","article-title":"Real-world experience with ceftolozane-tazobactam for multidrug-resistant Gram-negative bacterial infections","volume":"64","author":"Jorgensen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.064_bib0012","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.09.064_bib0013","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.09.064_bib0014","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2021.09.064_bib0015","series-title":"40th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2020)","article-title":"Outcomes in patients with failure of initial antibiotic therapy for hospital-acquired\/ventilator-associated bacterial pneumonia prior to enrollment in the phase 3 ASPECT-NP trial of ceftolozane\/tazobactam versus meropenem","author":"Kollef","year":"2020"},{"key":"10.1016\/j.ijid.2021.09.064_bib0016","doi-asserted-by":"crossref","first-page":"E95","DOI":"10.3390\/microorganisms9010095","article-title":"Spread of carbapenem-resistant Gram-negatives and Candida auris during the COVID-19 pandemic in critically ill patients: one step back in antimicrobial stewardship?","volume":"9","author":"Magnasco","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijid.2021.09.064_bib0017","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.09.064_bib0018","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012\u201315)","volume":"72","author":"Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.09.064_bib0019","series-title":"ESCMID Conference on Coronavirus Disease (ECCVID)","first-page":"434","article-title":"Incidence of infections and antimicrobial usage among US hospitalized patients with and without SARS CoV-2 infection: a multicenter evaluation","author":"Puzniak","year":"2020"},{"key":"10.1016\/j.ijid.2021.09.064_bib0020","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00134-020-06323-9","article-title":"Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study","volume":"47","author":"Rouze","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijid.2021.09.064_bib0021","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u20132012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.09.064_bib0022","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2014.04.004","article-title":"Ceftolozane\/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2021.09.064_bib0023","doi-asserted-by":"crossref","first-page":"e01587","DOI":"10.1128\/AAC.01587-18","article-title":"Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. Census Divisions: results from the 2017 INFORM Program","volume":"62","author":"Sader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.064_bib0024","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1093\/cid\/ciaa121","article-title":"Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing position statements on polymyxin B and colistin clinical breakpoints","volume":"71","author":"Satlin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.09.064_bib0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/mdr.2017.0266","volume":"24","author":"Shortridge","year":"2018","journal-title":"Microb Drug Resist"},{"issue":"Suppl. 1","key":"10.1016\/j.ijid.2021.09.064_bib0026","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/ofid\/ofy343","article-title":"Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 years from the SENTRY Antimicrobial Surveillance Program, 1997\u20132016","volume":"6","author":"Shortridge","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2021.09.064_bib0027","doi-asserted-by":"crossref","first-page":"ofz240","DOI":"10.1093\/ofid\/ofz240","article-title":"Comparison of the in vitro susceptibility of ceftolozane-tazobactam with the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aeruginosa from ICU patients with bloodstream infections or pneumonia","volume":"6","author":"Shortridge","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2021.09.064_bib0028","doi-asserted-by":"crossref","first-page":"ofab311","DOI":"10.1093\/ofid\/ofab311","article-title":"Cefiderocol activity against clinical Pseudomonas aeruginosa isolates exhibiting ceftolozane-tazobactam resistance","volume":"8","author":"Simner","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2021.09.064_bib0029","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America antimicrobial resistant treatment guidance: Gram-negative bacterial infections","volume":"72","author":"Tamma","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.09.064_bib0030","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2021.09.064_bib0031","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2021.09.064_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2019.296","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015\u20132017","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijid.2021.09.064_bib0033","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-020-03091-2","article-title":"Update of the treatment of nosocomial pneumonia in the ICU","volume":"24","author":"Zaragoza","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.ijid.2021.09.064_bib0034","series-title":"ZERBAXA (R) (ceftolozane tazobactam) prescribing information","year":"2020"},{"key":"10.1016\/j.ijid.2021.09.064_bib0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/beta-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221007773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221007773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:04:56Z","timestamp":1761120296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221007773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":35,"alternative-id":["S1201971221007773"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.09.064","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015\u20132018","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.09.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}